EP0489898A1 - Self-emulsifying glasses - Google Patents
Self-emulsifying glassesInfo
- Publication number
- EP0489898A1 EP0489898A1 EP91912696A EP91912696A EP0489898A1 EP 0489898 A1 EP0489898 A1 EP 0489898A1 EP 91912696 A EP91912696 A EP 91912696A EP 91912696 A EP91912696 A EP 91912696A EP 0489898 A1 EP0489898 A1 EP 0489898A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- glass
- emulsion
- oil
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011521 glass Substances 0.000 title claims abstract description 338
- 239000000839 emulsion Substances 0.000 claims abstract description 387
- 150000001875 compounds Chemical class 0.000 claims abstract description 164
- 238000000034 method Methods 0.000 claims abstract description 154
- 239000011159 matrix material Substances 0.000 claims abstract description 138
- 239000000463 material Substances 0.000 claims abstract description 109
- 239000008346 aqueous phase Substances 0.000 claims abstract description 102
- 239000002904 solvent Substances 0.000 claims abstract description 96
- 239000000203 mixture Substances 0.000 claims abstract description 82
- 239000007762 w/o emulsion Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 189
- 229930006000 Sucrose Natural products 0.000 claims description 102
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 102
- 239000005720 sucrose Substances 0.000 claims description 102
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 79
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 79
- 239000004480 active ingredient Substances 0.000 claims description 77
- 239000002480 mineral oil Substances 0.000 claims description 50
- 239000008307 w/o/w-emulsion Substances 0.000 claims description 40
- 239000003995 emulsifying agent Substances 0.000 claims description 34
- 235000010446 mineral oil Nutrition 0.000 claims description 29
- 239000007764 o/w emulsion Substances 0.000 claims description 29
- 150000002632 lipids Chemical class 0.000 claims description 26
- 229920002774 Maltodextrin Polymers 0.000 claims description 25
- 235000003599 food sweetener Nutrition 0.000 claims description 24
- 239000003765 sweetening agent Substances 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000005913 Maltodextrin Substances 0.000 claims description 19
- 229940035034 maltodextrin Drugs 0.000 claims description 19
- 235000009508 confectionery Nutrition 0.000 claims description 18
- 230000008018 melting Effects 0.000 claims description 15
- 238000002844 melting Methods 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 12
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
- 230000002209 hydrophobic effect Effects 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 11
- 239000003813 safflower oil Substances 0.000 claims description 11
- 229920003169 water-soluble polymer Polymers 0.000 claims description 11
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 10
- 150000002016 disaccharides Chemical class 0.000 claims description 10
- 239000004006 olive oil Substances 0.000 claims description 10
- 235000019485 Safflower oil Nutrition 0.000 claims description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 239000008177 pharmaceutical agent Substances 0.000 claims description 9
- 235000005713 safflower oil Nutrition 0.000 claims description 9
- 239000005715 Fructose Substances 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 229940109275 cyclamate Drugs 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- 239000008259 solid foam Substances 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- 239000002285 corn oil Substances 0.000 claims description 7
- 239000000312 peanut oil Substances 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 235000019483 Peanut oil Nutrition 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- IVILBNIXEFKQHQ-UHFFFAOYSA-N 1-fluoro-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene Chemical compound C1CCCC2C(F)CCCC21 IVILBNIXEFKQHQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 7
- 239000011149 active material Substances 0.000 claims 2
- 239000002195 soluble material Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 abstract description 100
- 239000012071 phase Substances 0.000 abstract description 82
- 235000013305 food Nutrition 0.000 abstract description 16
- 239000002537 cosmetic Substances 0.000 abstract description 12
- 230000001804 emulsifying effect Effects 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 8
- 239000003921 oil Substances 0.000 description 111
- 235000019198 oils Nutrition 0.000 description 98
- 238000002360 preparation method Methods 0.000 description 60
- 239000004094 surface-active agent Substances 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 33
- 239000003814 drug Substances 0.000 description 31
- 239000006185 dispersion Substances 0.000 description 29
- 239000007864 aqueous solution Substances 0.000 description 28
- 239000002245 particle Substances 0.000 description 27
- 239000012153 distilled water Substances 0.000 description 25
- 230000006870 function Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 238000002156 mixing Methods 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 229940097789 heavy mineral oil Drugs 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000005191 phase separation Methods 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 239000000084 colloidal system Substances 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000009477 glass transition Effects 0.000 description 13
- 239000000155 melt Substances 0.000 description 13
- 231100000331 toxic Toxicity 0.000 description 13
- 230000002588 toxic effect Effects 0.000 description 13
- -1 cyclamates Chemical class 0.000 description 11
- 238000012377 drug delivery Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 235000019204 saccharin Nutrition 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 238000005336 cracking Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 150000005846 sugar alcohols Chemical class 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000003633 blood substitute Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 229940124447 delivery agent Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001757 thermogravimetry curve Methods 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000007499 fusion processing Methods 0.000 description 6
- 230000000622 irritating effect Effects 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000006069 physical mixture Substances 0.000 description 6
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940059904 light mineral oil Drugs 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000003381 solubilizing effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000019605 sweet taste sensations Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 238000003260 vortexing Methods 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- PBKZPPIHUVSDNM-WNHSNXHDSA-N canrenoic acid Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC(O)=O)[C@@H]4[C@@H]3C=CC2=C1 PBKZPPIHUVSDNM-WNHSNXHDSA-N 0.000 description 4
- 229960002823 canrenoic acid Drugs 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 229960004755 ceftriaxone Drugs 0.000 description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 4
- 238000004581 coalescence Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 229950011087 perflunafene Drugs 0.000 description 4
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 229940081974 saccharin Drugs 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical class NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004692 intercellular junction Anatomy 0.000 description 3
- 229960001632 labetalol Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002404 acyltransferase inhibitor Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 239000002920 hazardous waste Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 239000010891 toxic waste Substances 0.000 description 2
- 229940108522 trandate Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241000723554 Pontia occidentalis Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QTBMDDQRDDABNC-UHFFFAOYSA-N [4-dibutoxyphosphoryl-3-(dibutoxyphosphorylmethyl)butoxy]benzene Chemical compound CCCCOP(=O)(OCCCC)CC(CP(=O)(OCCCC)OCCCC)CCOC1=CC=CC=C1 QTBMDDQRDDABNC-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229950000537 belfosdil Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000156 glass melt Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000003151 isocoumarinyl group Chemical class C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical class FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- LJFWQNJLLOFIJK-UHFFFAOYSA-N solvent violet 13 Chemical compound C1=CC(C)=CC=C1NC1=CC=C(O)C2=C1C(=O)C1=CC=CC=C1C2=O LJFWQNJLLOFIJK-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004108 vegetable carbon Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D10/00—Batters, dough or mixtures before baking
- A21D10/002—Dough mixes; Baking or bread improvers; Premixes
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/18—Carbohydrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention is in the field of emulsion technology and relates more specifically to compositions and methods for the preparation of emulsions and multiple emulsion and applications of such compositions and emulsions in the pharmaceutical, food or cosmetic fields.
- a number of pharmaceuticals are abandoned every year in the pharmaceutical industry not because the compounds are found to be inactive, but rather because they cannot be solubilized in an FDA approved solvent for delivery to the patient. This problem is quite common for chemotherapeutic agents, which can have extremely low or no water solubility due to their nonpolar nature. Additionally, compounds useful in the cosmetic, food, liquor, photographic, chemical or biomedical industries, may currently not be utilized for lack of an effective method to keep them solubilized or suspended. A method and vehicle that can solubilize or suspend such nonpolar compounds have numerous pharmaceutical and industrial applications. In general, the method for preparation of a vehicle for solubilizing nonpolar material should preferably be simple, i.e., should not involve numerous process steps or special skills to manufacture. It is also preferred that the method be economical, e.g., not involve a great deal of energy input.
- the vehicle should preferably be capable of lengthy storage without compromising its effectiveness as a delivery agent.
- the vehicle should be capable of being stored in a compact form. For example, if the vehicle can be stored as a dry solid, this can reduce the vehicle's weight and volume, which in turn can reduce transportation and storage costs.
- a vehicle If such a vehicle is to have use for pharmaceuticals, foods or other comestibles, it should not contain toxic materials. Additionally, such vehicles preferably do not impart an unpleasant or disagreeable flavor to edible products incorporated in them. Vehicles for topical applications, in pharmaceutical or cosmetic applications, should be non-toxic and non-irritating. Many surfactants are toxic, can cause irritation or can impart undesirable flavors; thus, they have limited use for pharmaceuticals or edible products.
- An ideal vehicle should be stable at a variety of pHs and temperatures to ensure its widest application.
- the vehicle should preferably be capable of leaving the vascular system to enter intercellular fluids so as to deliver the pharmaceutical to cells.
- the vehicle size should be less than about 200 ⁇ (0.2 ⁇ m).
- Existing methods and vehicles to solubilize lipophilic compounds can involve complex methods of manufacture, requiring highly skilled labor, or can require the input of a considerable amount of energy.
- Existing methods and vehicles can also involve components that are toxic or are sensitive to variations in pH and temperature.
- Such methods and vehicles, particularly those applied to pharmaceutical use include surfactant-containing emulsions and multiple emulsions, liposomes, glass dispersions and coprecipitates.
- Emulsions in the prior art while capable of solubilizing or suspending hydrophobic compounds in an aqueous environment, can be expensive to manufacture, can be unstable and usually contain toxic surfactants. The expense of manufacture is due largely to the use of energy-consuming devices that impart sufficient shear force to mix the phases and produce the appropriate particle size (A. Weiner (1990) BioPharm 2: 16-21). Shear stress devices, such as colloid mills, rotary-blade mixers, valve-type homogenizers, the Microfluidizer, French press pressure systems, ultrasonic baths or sprayers, and membrane based extruders, require considerable energy to produce the desired particle size. The operation of these devices requires the additional expense of skilled labor (P.
- Water-in-oil-in-water emulsions for example, can be employed to carry, transport or protect water-soluble compounds in their internal aqueous phase.
- the internal oil phase of such multiple emulsions can solubilize lipid-soluble compounds.
- Multiple emulsions can be generated when an emulsion inverts from one type to another or by re-emulsification of a primary emulsion (Florence, A.T. and Whitehill, D. (1982) Int'l. J. Pharmaceutics 11:277-308; Matsumoto (1983) J. Colloid Interface Sci. 94:362-368; Frenkel et al. (1983) J. Colloid Interface Sci. 94: 174-178).
- gelatin sphere-in-oil-in-water multiple emulsions have been described in relation to their potential use in drug delivery (Yoshioka et al. (1982) Chem. Pharm. Bull. 30:1406-1415). In these systems the internal water droplets are replaced with gelled gelatin microspheres.
- the S/O emulsion was formed by ultrasonication of an oil phase containing surfactants and an aqueous gelatin solution (20%).
- the S/O/W emulsion was generated by dispersing the S/O emulsion into another aqueous gelatin (1%) solution. Lyophilization of the S/O/W emulsion resulted in "bulky piles of oil droplets" which on situation gave the original S/O/W emulsion.
- the energy input necessary to produce the desired particle size can be reduced by using combinations of emulsifying agents that closely match the hydrophile-lipophile balance (HLB) requirement of the lipid phase (A. Weiner (1990) BioPharm 2: 16-17).
- HLB hydrophile-lipophile balance
- most of these agents are irritating and have limited in vivo use (Swarbrick, J. (1965) J. Pharm. Sci. 54:1229).
- the necessity of concentrated irritating emulsifiers can severely limit the use of emulsifier-containing preparations in pharmaceutical applications.
- Emulsifier-containing emulsions also can exhibit instability to changes in pH and temperature, resulting in coalescence of the emulsion particles and ultimately in phase separation (J. Collett & L. Koo (1975) J. Pharm. Sci. 64: 1253; and P. Elworthy & F. Lipscomb (1968) J. Pharm. Pharmacol. 20:817).
- Liposomes are a thermodynamically stable dispersal system (H. Hauser (1984) Biochem. Biophys. Acta 772:37) capable of solubilizing compounds (A. Janoff et al. (1985) Euro. Patent Publ. No. 185680). Liposomes can, however, be unstable under certain conditions (L. Guo et al. (1980) Lipid Res. 21:993; C. Alving & R. Richards (1983) The Liposomes (M. Ostro ed.; D. Papahadjopoulas (1962) Proc. Soc. Exper. Biol. 111:412). Liposomes may be antigenic/immunogenic (C.Alving (1986) Chem. Phys.
- Lipids 4.0:303 can be too large (at least 600 ⁇ in diameter) to allow their transport through intercellular junctions in the vascular endothelium (N. Simionesu et al. (1975) J. Cell Biol. 64: 586; G. Gregoriadis (1979) Drug Carriers in Biology and Medicine, pp. 287-341). Moreover, the manufacture of liposomes is expensive in that it requires special skills and equipment and can be energy intensive (F. Defrise-Quertain et al. (1984) Liposome Technology, Vol. 2, pp. 1-17; and F. Szoka & D. Papahadjopoulis (1980) Ann. Rev. Biophys. Bioeng. 9:467; A. Weiner (1990) Biopharm 2: 17-18; Ostro (1988) Liposomes as Drug Carriers, p.855 (G. Gregoriadis, ed.)).
- Glass dispersions are solids formed by incorporating a medicinal within a melt, thus forming a glass dispersion upon solidification. Such materials are used in tablets, capsules or other dosage units to increase dissolution, absorption, and therapeutic efficacy of medicinals.
- the glass solid dispersion is formed by the melting or fusion of a carrier and a drug followed by rapid cooling.
- the carrier is soluble in a solvent; mixing with the solvent results in the rapid dissolution of the carrier and the molecular dispersion of the drug in the matrix of the carrier.
- One disadvantage of this method is that either the drugs or carriers can decompose, evaporate or be oxidized during the fusion process (W. Chiou & S. Riegelman (1971) J. Pharm. Sci. 60:1283).
- a further disadvantage is the manufacturing expense incurred by the input of heat energy.
- the drug must be soluble or miscible in the fused carrier compound in order to form a glass dispersion solid.
- the investigator was unable to disperse or dissolve castor oil in molten mannitol.
- References that describe glass solutions using saccharides as carrier compounds include L. Allen et al. (1977) J. Pharm. Sci. 66:494-496; W. Chiou & S. Riegelman (1971) J. Pharm. Sci. 60:1281-1302; and J. Kanig (1964), supra.
- Coprecipitate solids can be mixed with a solvent to form a solution.
- Coprecipitate solids are prepared by dissolving a physical mixture of two solid components in a common solvent, followed by evaporation of the solvent
- Coprecipitates have been produced with various polymers.
- a disadvantage associated with existing coprecipitate methods is that a common solvent must be found for both the drug and the carrier. This necessarily restricts the possible combinations of drug and carrier to those that have a common and non-toxic solvent.
- the novel method of this invention supplies emulsion systems and multiple emulsion systems that obviate many problems inherent in the foregoing methods and systems.
- the method provides a novel glass that, on addition of a selected liquid aqueous phase, forms an emulsion that contains no toxic surfactants (or in the case of multiple emulsions requires only one surfactant).
- the method of producing the glass is simple.
- An emulsion can be generated from the glass of this invention by simply contacting it with a suitable aqueous phase (e.g., water); no work is necessary to form the emulsion.
- a suitable aqueous phase e.g., water
- the resulting emulsion is stable under a variety of pH and temperature conditions.
- the emulsion can be formulated to have particles less than about 0.2 ⁇ m in diameter to allow transport through vascular endothelial intercellular junctions.
- the emulsions of the subject invention contain an oil phase that can optionally be used to solubilize hydrophobic active ingredients. Further, the inclusion of an oil component in the subject emulsion obviates the problem of limited combinations of drug and carrier inherent in known coprecipitation methods. In contrast to existing melt-fusion techniques, the present method does not require the application of high temperatures which can inactivate or decomposed solubilized compounds.
- the method of the present invention is applicable to solid/oil combinations in which the oil phase can be utilized to solubilize a lipophilic compound.
- Meltfusion methods and coprecipitation methods have not been described for the production of multiple emulsions.
- the methods and compositions described herein will be useful in a wide range of emulsion applications and will be particularly attractive for applications in the pharmaceutical, food and cosmetics industries.
- This invention provides methods and compositions which are useful for the preparation of stable emulsions. More particularly, glass compositions comprising a water- soluble, non-surface active matrix compound and an oleaginous material from which emulsions can be readily formed by contacting the glass with an aqueous phase are provided.
- the glasses of the present invention are designated self-emulsifying glasses.
- Emulsion and multiple emulsion compositions including, among others, oil-in-water emulsions and water-in-oil-in-water emulsions are provided.
- a variety of water-soluble and/or lipid soluble active ingredients can be introduced into the self-emulsifying glasses and emulsion compositions of the present invention employing the methods and compositions described hereinafter.
- the self-emulsifying glasses of the present invention are useful for the generation of emulsions and multiple emulsions, particularly oil-in-water emulsions and water- in-oil-in-water emulsions.
- the subject self-emulsifying glasses are particularly useful in pharmaceutical, food and cosmetic applications to form emulsions which do not contain surfactants or which avoid the use of multiple surfactants.
- the compositions and methods of the present invention are also particularly useful in applications which require stable multiple emulsions.
- the subject glasses can be stored under appropriate storage conditions for long periods without loss of emulsion-forming capability. Emulsions can be generated from the glass when needed by contact with an aqueous phase suitable for the desired application.
- the subject self-emulsifying glasses are also useful as drug delivery agents, to be incorporated in capsules, tablets or other dosage forms for oral administration to humans or animals, as a means for delivery of pharmaceutical agents or other active ingredients.
- the stable water-in-oil and oil-in-water emulsions produced from self-emulsifying glasses of the present invention do not require art-recognized surfactants or emulsifying agents.
- the matrix compounds of the present invention are not surface active agents, surfactants or emulsifying agents.
- the stable multiple emulsions e.g., water-in-oil-in-water emulsions, of the present invention require a stable water-in-oil emulsion, preferably a water- in-oil emulsion including an emulsifying agent, but do not require a second water-soluble surfactant to obtain the multiple emulsion.
- Avoiding the use of surfactants is beneficial, particularly in pharmaceutical, food and cosmetic applications, because of their potential for toxic, irritant or allergic effect. Avoiding the use of a second surfactant in multiple emulsions avoids the problem of surfactant mixing or migration which can limit the stability of multiple emulsions.
- Emulsion compositions produced from the subject selfemulsifying glasses can generally be employed in any application for which emulsions or multiple emulsions are recognized to be useful.
- emulsions are employed to carry, transport, deliver, or protect active ingredients or alternatively to separate and isolate a desired component from a mixture or remove an undesirable component from a mixture.
- the subject emulsions are useful in all such general applications of emulsions and multiple emulsions.
- monosaccharides, disaccharides and non- sugar sweeteners such as cyclamates, saccharines and water soluble polymers including polyvinylpyrrolidones (PVP), cellulose derivatives and maltodextrins function as matrix compounds in the formation of the self-emulsifying glasses of the present invention.
- Saccharides including but not limited to sucrose, fructose and trehalose function as matrix compounds in the subject glasses.
- Preferred non- polymeric matrix compounds are molecules which taste-sweet, more preferred are molecules which are at least about as sweet as sucrose.
- Non-sugar sweeteners useful as matrix compounds include various sweet-tasting molecules including but not limited to amino acids, amino acid derivatives, Aspartame (Trademark) and derivatives thereof, and sulfamates including cyclamates, saccharines, acesulfams and derivatives thereof.
- Non-polymeric molecules that posses a tripartite glucophore comprising three structural features: a polarized bond or proton donor, an electronegative atom, and a region capable of hydrophobic bonding or dispersive bonding are of use as matrix compounds in the selfemulsifying glasses prepared using the solvent methods of the present invention.
- Molecules possessing a tripartite glucophore having the three structural features of a proton donor, an electronegative atom and a hydrophobic region are of particular use as matrix compounds in the solvent-based methods of preparation of glasses of the present invention.
- Molecules possessing such tripartite glucophores are of particular use in glass preparation methods which employ water as a solvent.
- Polymeric matrix compounds that are useful in self- emulsifying glasses of the present invention include among others PVPs, maltodextrins and cellulose derivatives.
- Crosslinked and non-crosslinked PVPs ranging in molecular weight from about 15 to 70 thousand can be processed by the methods described herein to form self-emulsifying glasses.
- Water-soluble cellulose derivatives including carboxymethylcellulose and hydroxyalkycelluloses including hydroxmethyl- and hydroxypropylcelluloses can be processed by the methods described herein to form self-emulsifying glasses.
- Maltodextrins of the present invention are dextrose copolymers with starch, classified as having dextrose equivalents from about 5 to about 25. Both agglomerated and non-agglomerated forms of maltodextrin function in the compositions and methods of the present invention.
- the various matrix compounds can be admixed to form glasses of the present invention.
- Employing a mixture of matrix components can, for example, lead to self-emulsifying glasses with higher glass transition temperatures.
- the higher the glass transition temperature the more kinetically stable the glass. Glasses with higher glass transition temperatures will be generally more stable to storage and have longer shelf-lives. It is generally preferable that glass transition temperatures be about 20oC or more above room temperature.
- Mixtures of non-polymeric matrix compounds, such as sucrose, with polymeric matrix compounds, such as maltodextrin result in glasses with higher transition temperatures compared to glasses formed with the non-polymeric matrix compound alone.
- the use of a mixture of sucrose and maltodextrin as the matrix compound results in glasses having higher glass transition temperature than sucrose- based glasses.
- a mixture of sucrose and 3% by weight maltodextrin when combined with mineral oil and processed by the solvent method described herein results in a self-emulsifying glass having a glass transition above about 180°C.
- Oleaginous materials useful in the compositions and methods of the present invention include a variety of oils, particularly those which are in liquid form at about room temperature.
- Oils useful particularly in pharmaceutical, cosmetic or food applications of emulsions and glasses include but are not limited to fluorodecalin, mineral oil (heavy or light), vegetable oil, peanut oil, soybean oil, safflower oil, corn oil, olive oil, oil components thereof, and mixtures thereof.
- Oleaginous materials also include water-in-oil emulsions, i.e., in which the oil phase is the external phase of the emulsion and which posses the bulk properties of an oil.
- the aqueous phase of the water-in- oil emulsion can incorporate a water-soluble activeingredient.
- the oil phase of the water-in-oil emulsion can incorporate a lipid-soluble active ingredient.
- any type of water-in-oil emulsion produced by any known process and containing any surfactant useful for producing such an emulsion, will function as an oleaginous material in the glasses of the present invention.
- the methods employed for production of the water-in-oil emulsion must be compatible with any active ingredient that is incorporated therein.
- Preferred water-in-oil emulsions employ a suitable emulsifying agent, for example a lipid soluble surfactant appropriate for forming a water-in-oil emulsion, including but not limited to those having HLB values less than about 5.5.
- the weight ratio of the matrix compound to the oleaginous material is at least about 2:1.
- the weight ratio of matrix compound to oleaginous material is more preferably between about 2:1 and 20:1 and most preferably between about 2:1 and 10:1.
- Self-emulsifying glasses are preferably prepared by the solvent method described herein which involves the steps of combining an oleaginous material with a non-surface active matrix compound, as. defined herein, and a sufficient amount of a solvent such that substantially all of the matrix compound is dissolved to form a combination such that the combination is not a stable emulsion followed by removing the solvent from the combination such that a glass results.
- the solvent employed can include but is not limited to water, aqueous solvents, aqueous alcohols, ethanol, methanol, and organic solvents in which the matrix compound is soluble including among others chloroform. Water and aqueous solvents including aqueous solvents and aqueous alcohols are preferred.
- Chloroform is, in addition, preferred for use with the matrix compound PVP polymers.
- the method can be modified, if desired, to add sufficient solvent to dissolve both the matrix compound and the oleaginous material.
- the matrix compound and oleaginous material are preferably combined such that the weight ratio of the matrix compound to the oleaginous material is at least about 2:1.
- Solvent removal is preferably done by evaporation by application of a vacuum accompanied by non-vigorous mixing, i.e., non- emulsive mixing, most preferably by rotoevaporation.
- the preferred solvent for use in cases in which the oleaginous material is a water-in-oil emulsion is water. Solvent is removed until a dry-appearing solid, solid foam or film is produced. In some cases, rotoevaporation results in bubbling of the combination and the solid resulting from removal of solvent has the appearance of a solid foam.
- Glasses formed using non- polymeric matrix compounds or mixtures of polymeric and non-polymeric matrix compounds often retain some level of short or medium range molecular order, designated microcrystallinity herein, as measured by differential scanning calorimetry (DSC).
- DSC differential scanning calorimetry
- Glasses which are fully amorphous, as measured by X-ray diffraction and DSC can be prepared by the solvent method described herein.
- Fully amorphous glasses may be very hygroscopic and the absorption of significant amounts of water into glasses is detrimental to their functionality and shelf-life.
- glasses retaining some level of microcrystallinity from about 10% to 60% microcrystallinity as measured by DSC, are preferred.
- the subject glasses do not retain more than about 10% long range molecular order as measured by X-ray diffraction.
- the solvent be removed at a rate that is fast enough to prevent the formation of significant, i.e., greater than about 10%, long range molecular order via crystallization of the non- polymer component of the matrix compound. This can generally be achieved if the rate of solvent removal is faster than the rate of crystallization of any matrix component from the solvent solution.
- the process steps can in many cases be performed at about room temperature. It is preferred that the process steps are performed at the lowest temperatures possible which allow generation of a dry appearing solid. It is more preferred that the process steps are performed at temperatures less than about 50°C.
- the process steps should be performed to avoid melting or decomposition of the matrix compound, i.e., the process should be performed at temperatures less than about the melting point or decomposition point of the matrix compound. Many, if not all, matrix compounds will have melting points below about 140°C.
- process steps should preferably be performed at temperatures which ensure that the active ingredient will not decompose or be significantly inactivated.
- Lipid soluble active ingredients can be incorporated into the self-emulsifying glasses by being added to the oleaginous material prior to or simultaneously with its combination with the matrix compound.
- Water-soluble active ingredients can be incorporated into the self-emulsifying glasses of the present invention in the aqueous phase of a water-in-oil emulsion oleaginous material. The water-in- oil emulsion must be formed prior to its combination with the matrix compound.
- Emulsions and multiple emulsions are prepared from the self-emulsifying glasses of the present invention by addition of a sufficient amount of an aqueous phase such that the desired type of emulsion, e.g., oil-in-water, water-in-oil or water-in-oil-in-water is formed.
- aqueous phases depend on the desired emulsion application and include but are not limited to acidic or basic aqueous solutions with pH ranging from about 1 to 10 and aqueous alcohol having an alcohol content less than about 95%
- the subject emulsions are generated by simply contacting the self-emulsifying glass with the aqueous phase. No mixing is necessary to generate the emulsion from the glass.
- Active ingredients that are chemical reactants, chelating agents, catalysts, enzymes, biological cells, pharmaceutical agents, cosmetic and personal care agents including sunscreens, antiperspirants, hypoallergenic agents and the like, and food additives including flavoring agents, coloring agents, perservatives and the like can be introduced into the self-emulsifying glasses and emulsion compositions of the present invention.
- Pharmaceutical agents useful in the compositions of the present invention include but are not limited to peptides, proteins, vaccines, therapeutic enzymes, therapeutic antibodies, hormones, antimicrobial agents, lipoxygenase inhibitors , acyl transf erase inhibitors , chemotherapeutic agents, anticoagulant agents, thrombolytic agents or colony stimulating factors .
- More specifically pharmaceutical agents include but are not limited to dismutases, erythropoietins, interferons, interleukins, monoclonal antibodies, tumor necrosis factors, human growth hormone, insulin, ceftriaxone, cephalosporins, acetaminophen, a beta-blocker, trandate, labetol, 5-fluorouracil, methotrexate, mechlorethamine HCl, urease, LH-RH analogs, analogs of gonadotropin-releasing hormones.
- the methods and compositions of the present invention are particularly useful in the preparation of drug delivery agents for such pharmaceutically active ingredients.
- the methods and compositions described herein can be employed to improve the means of delivery of pharmaceuticals by protecting a patient from deleterious effects of pharmaceuticals for example those having an unpleasant taste, a general irritant effect, a gastrointestinal irritant effect, or a toxic effect.
- the methods and compositions described herein can also be used to generally protect active ingredients from decomposition or inactivation. For example, moisture-sensitive and/or oxygen-sensitive active ingredients can be protected. Water-soluble active ingredients are introduced into the aqueous or water phases of the subject emulsions. Lipid- soluble active ingredients are introduced into the oleaginous or oil phases of the subject inventions.
- the methods of the present invention do not require the application of high temperatures to produce the subject glasses.
- compositions of the present invention are consequently particularly useful with any water-soluble or lipid-soluble temperature sensitive active ingredients.
- the methods of the present invention are of more particular use with active ingredients which are partially or fully inactivated, or decompose at temperatures above about 50°C.
- Figure 1 is a graph of turbidity as a function of time (minutes) obtained from absorbance measurements at 400 nm.
- the graph compares turbidity of two oil-in-water emulsions produced from self-emulsifying glasses: one having water as the external phase (solid diamonds) and one having normal saline as the external phase (open squares) with a dispersion of a physical mixture of the same components (solid squares).
- the self-emulsifying glasses were prepared using sucrose and mineral oil in a 6:1 weight ratio. The dispersion was prepared by vortexing (20 min.) a physical mixture of sucrose, mineral oil and water having the same relative composition as the emulsions. All measurements were made at 25°C.
- Figure 2 is a graph of conductivity of an emulsion formed from a self-emulsifying glass as a function of the weight content. Water content is expressed as the weight% of water of the emulsion. Conductivity is expressed as conductivity relative to water. All measurements were at 25°C.
- the self-emulsifying glass contained sucrose and mineral oil in the weight ratio 4:1.
- Figure 3 is a graph of viscosity of an emulsion with a sucrose to mineral oil weight ratio 6:1 at 25°C as a function of shear rate in rpm. Measurements were made as a function of both increasing shear rate, open squares, and decreasing shear rate, closed diamonds.
- Figure 4 is an X-ray diffractogram of a sucrose-mineral oil self-emulsifying glass produced by the solvent method of the present invention.
- the diffractogram of the glass, trace B is compared to a diffractogram of a physical mixture of sucrose and mineral oil, trace A.
- Figure 5 is a comparison of differential scanning calorimetry thermograms for self-emulsifying glasses which form W/O/W emulsions on contact with an aqueous phase.
- Thermogram A is of a glass prepared using a mixture of sucrose and maltodextrin (3% by weight, mixture designated White Di-Pac) as the matrix compound.
- Thermogram B is of a glass prepared using sucrose as the matrix compound.
- the graph displays normalized heat flow (Watts/gram) as a function of temperature (°C).
- An emulsion is a dispersion of one immiscible liquid in another with the dispersed liquid in the form of droplets.
- the dispersed liquid is the internal phase (or discontinuous phase) and the other liquid is the external phase.
- Emulsions are most typically employed with an aqueous phase and an oil phase.
- an aqueous phase is dispersed in an oil phase.
- an oil phase is dispersed in an aqueous phase.
- Emulsions are inherently unstable; The internal phase will coalesce with time and the emulsion will crack. It has been generally accepted that an emulsifying agent (surfactant) is required to stabilize an emulsion.
- an emulsifying agent surfactant
- conventional stable emulsions contain at least one emulsifying agent.
- the type of emulsion can be determined in several ways.
- An emulsion will typicaally have the bulk appearance of its external phase, i.e., a W/O emulsion has the appearance of an oil, an O/W emulsion has the appearance of water.
- Several more quantitative methods for determining the type of emulsion are dye solubility tests (a water-soluble dye tints an O/W emulsion, but not a W/O emulsion) and electrical conductivity tests (a W/O emulsion generally does not conduct an electric current).
- emulsions are more complex types of emulsions in which the dispersed droplets contain smaller dispersed droplets of an immiscible liquid.
- (W/O/W) emulsion contains droplets of an oil in an external aqueous phase and the droplets of oil contain smaller droplets of an internal aqueous phase.
- the external and internal aqueous phases may be the same or different.
- Multiple emulsions have been prepared by emulsifying a primary O/W or W/O emulsion (see: Davis and Walker (1987) Multiple Emulsions as Targetable Delivery Systems Meth. Enzymol. 149:51-64). The formation of multiple emulsions has generally been believed to require the use of two surfactants having different HLB values (see: Davis and Walker, 1987; Florence and Whitehill (1981) J. Colloid Inter. Sci. 79: 243-256; Martin et al.
- W/O/W emulsions typically are stable for 24 to 48 hrs (Florence and Whitehall, 1981), however, under extreme conditions, stabilities up to 30 days have been achieved (Davis and Walker, 1987 and Garti et al., 1983).
- the emulsions and multiple emulsions of the present invention are generated by addition of a selected aqueous phase to a self-emulsifying glass.
- the self-emulsifying glass is prepared by combining a water-soluble, non-surface active matrix compound with an oleaginous material which can simply be an oil phase optionally containing a dissolved lipid-soluble active ingredient or a primary emulsion, for example a water-in-oil emulsion optionally containing a dissolved active ingredient.
- the self-emulsifying glasses of the present invention form emulsions on contact with a sufficient amount of an aqueous phase. Emulsion formation is almost immediate, requiring no significant energy input.
- the emulsion can be formed from the subject glasses by simply contacting the solid with an aqueous phase. This characteristic of the glass avoids process steps involving emulsive mixing such as agitation, homogenizing, microfluidizing, ultrasonication or processing in a colloid mill.
- the subject glasses which are precursors to simple emulsions contain no art-recognized surfactant.
- the self-emulsifying glasses which are precursors to multiple emulsions at most require a surfactant to form the primary emulsion.
- Simple two phase emulsions and multiple (i.e., three phase) emulsions can be prepared employing the selfemulsifying glasses described herein.
- a self-emulsifying glass precursor to a W/O/W emulsion is prepared from a mixture of a primary water-in-oil emulsion and a water- soluble, non-surface active carrier.
- the multiple emulsion can be formed from the glass on contact with an aqueous phase.
- the self-emulsifying glasses of the present invention can incorporate active ingredients such as pharmaceutical agents, reactive chemical agents, dyes, flavoring agents and the like, and can function as a vehicle for the delivery or solubilization of such active ingredients.
- Lipid soluble active ingredients can be incorporated into the oleaginous material of the glass.
- Water soluble active ingredients can be incorporated into self-emulsifying glasses in the aqueous phase of the water-in-oil emulsions.
- the self-emulsifying glasses of the present invention are prepared as solids, preferably as dry, non-oily solids.
- the glasses can be in the form of a powder, a solid foam or a film.
- the glass can be stored, if protected from extremes of humidity, for extended periods without loss of emulsion forming capability.
- glasses and liquids have only short-range molecular order.
- the nearest neighbor separations and bond angles are exactly equal while in a glass, the nearest neighbor separations are approximately equal over a few molecular distances. Practically this results in an inability to predict the location of a neighbor within the glass.
- crystallizing material may be differentiated easily from glasses by X-ray diffraction methods.
- a glass or liquid can only produce weak and diffuse diffraction effects, while crystallites can give strong and sharp diffraction effects. In this sense, a glass is also amorphous to X-ray diffraction (G. O. Jones, "Glass,” Wiley, New York, NY, 1971, pp. 5-8).
- a material may have numerous small discontinuous regions (microcrystalline regions) of crystallinity dispersed among amorphous regions that appear amorphous by X-ray diffraction.
- the quantity of such regions appear to be dependent on the method of preparation and physical properties of the respective materials.
- the self-emulsifying glasses of the present invention are amorphous materials as measured by X-ray crystallographic techniques. Materials having about 10% (by weight) or less long range crystallinity appear to be amorphous by X-ray methods. Certain of the glasses of the present invention appear to contain regions of microcrystallinity as measured by differential scanning calorimetry (DSC). The extent of microcrystallinity in a glass can vary significantly from essentially no microcrystallinity up to about 60% (by weight) microcrystallinity. The extent of microcrystallinity appears to depend on the extent of crystallization of components that occurs during processing of the glass.
- DSC differential scanning calorimetry
- glasses having little or no measurable microcrystallinity an be prepared by the solvent method of the present invention if siliconized glassware is employed during solvent removal.
- the extent of microcrystallinity in the glass does not effect the ability of the glass to form emulsions on contact with a aqueous phase.
- the glass having very low microcrystallinity levels can be very hygroscopic.
- the self-emulsifying glasses of the present invention are distinct from prior art dried emulsions and concentrated emulsions, since these compositions result from an existing stable emulsion which typically contains at least one emulsifying agent.
- existing dried emulsion precursors contain art-recognized surfactants.
- existing dried multiple emulsion precursors are distinct from the glasses of the present invention in that they are derived from formed multiple emulsions and contain at least two surfactants.
- the matrix compounds of the glasses of the present invention are water soluble, non-surface active compounds.
- Two classes of matrix compounds have been identified which can be employed to produce self-emulsifying glasses.
- One class includes monosaccharides and disaccharides, such as sucrose, trehalose, and fructose, sweeteners including on- saccharide sweeteners and synthetic sweeteners, such as cyclamates and saccharines.
- the other class of matrix compound includes water-soluble polymers such as polyvinylpyrrolidones, water-soluble cellulose derivatives and maltodextrins. Mixtures of two or more of the various matrix compounds can also be employed to produce selfemulsifying glasses.
- sweetener is any material that tastes sweet.
- the term sweetener is specifically intended to encompass sugars as well as molecules, compounds or mixtures other than sugars which taste sweet.
- Sweeteners include non-saccharide sweeteners, like sugar- alcohols, amino acids and sulfamates among many more.
- Non- saccharide sweeteners can be naturally-occurring compounds, e.g., sugar-alcohols and amino acids, or synthetic sweeteners, e.g., chlorinated sugars, Aspartame (Trademark for aspartylphenylalanine methyl ester), cyclamates or saccharines.
- Preferred sweeteners for use as a matrix compound in the solvent method of the present invention are those compounds or mixtures that are at least about as sweet as sucrose. It is preferred, at least for applications in the pharmaceutical, food and cosmetic fields that a matrix compound be non-toxic.
- self-emulsifying glasses could not readily be formed with glucose, lactose, maltose and the sugar alcohols mannitol and sorbitol, using water as a solvent. Lactose is significantly less soluble in water and sufficient lactose cannot be solubilized in water to allow glass formation via rotoevaporation. Glucose, mannitol and the sugar alcohols appear to have sufficient water solubility, but it was found that a dry solid glass could not be produced via rotoevaporation. It was found that self-emulsifying glasses could be produced from trehalose. The resultant trehalose-based glasses, however, did not appear to be dry solids.
- Glucose, maltose, lactose, sorbitol, mannitol and trehalose are all reported to be less sweet-tasting compared to sucrose.
- intensity of sweetness, compared to sucrose, of a potential matrix compound and the ability to produce a self-emulsifying glass employing that matrix by the water solvent method described herein.
- Sweet molecules are found among sugars; sugar derivatives: including hydrogenated, deoxy, anhydro and chlorinated sugars; amino acids; amino acid derivatives: including Aspartame (Trademark) and chlorinated amino acids; sulfamates including: saccharines, cyclamates and acesulfams; aminonitrobenzenes; dihyrochalcones; isocoumarines; certain proteins and peptides such as thaumatin and hernadulcin. Not all compounds of a particular type will be sweet and the intensity of sweetness among apparently similar compounds can change significantly. In some cases, only one of a pair of enantiomers will be sweet-tasting.
- a concept that rationalizes the sweetness of a variety of sweet-tasting molecules and relates sweetness to a three- dimensional structure involves a tripartite glucophore (see Lee, 1987, p. 231 and Kier, 1972).
- the tripartite glucophore is a structural feature associated with sweetness which consists of a polarized bond, designated AH or A, an electronegative atom, designated B and a third feature.
- AH or A a polarized bond
- B electronegative atom
- Examples of AH include O-H groups, N-H groups and C-H groups of cycloalkyl groups or aromatic rings.
- Examples of B include oxygen atoms, oxime groups, nitro groups, carbonyl groups, and S-O or SO 2 groups.
- the AH, B unit in the cyclamate and saccharin sweeteners are assigned to the NH-SO 2 moieties.
- the third feature, designated X herein, is associated with increasing intensity of sweetness.
- the X feature is described specifically as a lipophilic region or hydrophobic bonding area (Deutsch and Hansch (1966) Nature 211:75), or more generally as a region capable of dispersive bonding or a region susceptible to electrophilic attack (Kier, 1972).
- Examples of the X feature include alkyl and alkenyl groups, cycloalkyl and cycloalkenyl groups, aromatic rings, the C-2 substituent in aminonitrobenzenes. All three features are described as involved in binding of the sweet molecule to the receptor.
- the features of the tripartite glucophore form a triangle with the AH-B distance ranging from about 2.5-4.0 ⁇ , the AH-X distance ranging from about 3.1 to 5.2 ⁇ and the B-X distance ranging from about 5.2 to 7.4 A.
- the triangular tripartite glucophore structure is more narrowly depicted with a AH-B distance of about 2.6 ⁇ , a B-X distance of about 5.5 ⁇ and a X-AH distance of about 3.5 A.
- Intensity of sweetness is associated with better fit or improved binding in the receptor.
- Sweet-tasting compounds which possess a tripartite glucophore, particularly in which the X feature is a region capable of hydrophobic bonding, are useful in the preparation of self-emulsifying glasses via the water solvent method as described herein.
- Those compounds possessing the tripartite glucophore which are sweeter than sucrose are preferred matrix compounds for use in the compositions and methods of the present invention.
- Sweetness is generally compared to that of sucrose.
- Method for testing the relative sweetness of particular compounds are well-known in the art.
- Qualitative sweetness evaluation can simply be performed by individual taste-tests of solids or aqueous solutions. Care should be taken, however, in making such taste tests, since certain sweet compounds may be toxic.
- Taste-tests by a single individual may not be definitive due to partial taste-dysfunction or aberrations in an individual's sense of taste from the norm.
- Quantitative tests comparing relative sweetness of compounds are generally performed by special test-panels.
- the intensity of sweetness is often ranked compared to sucrose by determination of the concentration of an aqueous solution that will be iso-sweet with an aqueous solution of a known concentration of sucrose.
- a variety of literature sources are readily available which provide quantitative rankings of the sweetness of a variety of compounds (See, for example, Grant and Hatch's Chemical Dictionary (1987) 5th (and later) Editions, Grant and Grant, eds., McGraw-Hill, New York; Andres (1977) Low Calorie and Special Dietary Foods, CRC Press) It is important that the lipophilic region of the tripartite glucophore, or more correctly the lipophilic surface of sucrose, saccharin or cyclamates, not be confused with classical lipophilic region of emulsifying agents, e.g., long chain hydrocarbons.
- the second type of matrix compounds are polymers which are not sweet-tasting. These materials appear to have some structural similarity to some of sweet materials but no clear correlation between the structure of the polymers and their utility in self-emulsifying glasses is known.
- Polymeric matrix compounds include but are not limited to polyvinylpyrrolidones including members of that group containing any number of vinyl groups, water-soluble cellulose derivatives, both fully and partially derivatized, including among others carboxymethylcellulose and hydroxyalkylcellulose, and maltodextrins which are starch/dextrose copolymers.
- Matrix compounds in general, are chosen to be compatible with the oleaginous material, solvent and aqueous phase components of the formulations.
- the polymeric matrix compounds of the present invention do not taste-sweet, it is clear that the correlation between sweetness and the presence of a tripartite glucophore and the functionality of a compound for emulsion formation is not absolute, i.e., sweetness is sufficient but not required for matrix compounds that function in the formation of self-emulsifying glasses.
- the correlation between intensity of sweetness and function as a matrix compound in the present invention is useful for selecting candidate matrix compounds which can be readily assessed for suitability for use in the methods of the present invention by following the procedures described herein.
- Surface active agents or emulsifying agents are molecules that are preferentially adsorbed at interfaces.
- the adsorption or accumulation of emulsifying agents at the water/air interface sharply lowers the surface tension of water (see Becher, 1983, p. 111). Accumulation of surface active agents occurs lowering the surface tension until the water/air interface is saturated with the emulsifying agent, i.e., the plateau region. Once the surface is saturated with the emulsifying agent, additional emulsifying agent results in the formation of associated structures or micelles.
- Emulsifying agents reduce the surface tension by orientating at the water/air interface such that the non- polar region of the molecule is exposed to the air (relatively non-polar).
- the hydrophilic portions of the molecule tend to orientate towards the water.
- the three basic structural requirements for emulsifying agents are (i) lipophilic region, (ii) hydrophilic region, and (iii) a balance between the lipophilic and hydrophilic regions. It is important that there be a balance between the hydrophilic and lipophilic regions. For example, if a molecule is too hydrophilic it will locate where the water is located, i.e., in the bulk. Conversely, if a molecule is too lipophilic it may be completely expelled from the aqueous phase.
- the lipophilic region is commonly recognized as the hydrocarbon chain part of the molecule.
- lipophilic regions may be either saturated or unsaturated hydrocarbon chains or, less commonly, heterocyclic or aromatic ring systems.
- emulsifying agents are commonly found to have hydrocarbon chains from eight to eighteen methylene groups.
- the hydrophilic regions are characterized as to whether or not the region is anionic, cationic or non-ionic.
- This invention describes the use of certain molecules and classes of molecules that are not predicted to be surface active by conventional emulsification theory. These molecules and classes of molecules, designated matrix compounds herein, do not significantly decrease the surface tension of aqueous solutions and thus are not reported or anticipated to form associated structures, i.e., micelles. According to conventional understanding, the matrix compounds of this invention lack two of the three required structural requirements of emulsifying agents, namely a lipophilic region and therefore a hydrophilic/lipophilic balance. Matrix compounds of the present invention are therefore expected to be equally dispersed between the interface and the bulk (Hem et al. (1986) in "The Theory and Practice of Industrial Pharmacy", Third Edition, Lachman et al.
- sucrose is a matrix compound of the present invention.
- a sucrose molecule is regarded as a hydrophilic group and not surface active (J. G. Riess et al., Biomat., Art., Cells, Art., Org., 16:421-430 (1980)).
- surfactants are prepared from sucrose by esterification (mono- and diesters) with long chain fatty (a hydrocarbon region) acids such as stearic (C 18 H 36 O 2 ) and cocoaic acids (C 18 H 16 O 4 ) which provide a lipophilic region and thus surface activity.
- self-emulsifying as used herein has been applied to glasses formed from matrix compounds and an oleaginous material.
- the term refers to the emulsion- forming property of the glass and specifically to the ability to form an emulsion by simply contacting the glass with an aqueous phase.
- the oleaginous material of the present invention is a material that containing oils or glycerides and esters of fatty acids.
- the oleaginous material is preferably liquid at about room temperature.
- oils include but are not limited to natural and synthetic oils, mineral oil, vegetable oil, peanut oil, safflower oil, olive oil, corn oil, soybean oil, castor oil, linseed oil, petroleum and components thereof, fish oils and oils of animal origin, and fluorodecalins, including perfluorodecalin.
- the oleaginous material can include flavor oils, such as oils of spearmint, peppermint, wintergreen and the like. It is, however, preferred that a flavor oil is not the major component of the oleaginous material.
- the oil is selected to be appropriate for a given application and to be compatible with other components in an emulsion formulation. While some naturally occurring oils may contain small amounts of monoglycerides or other compounds that can act as emulsifying agents, these materials are not required to generate the emulsions of the present invention.
- Oleaginous materials also include water-in-oil emulsions. Such emulsions have bulk properties like an oil, specifically like the oil phase of the emulsion.
- the W/O emulsions contain an aqueous phase dispersed within the oil phase.
- the oil phase can include any of the oleaginous materials listed hereinabove.
- the aqueous phase can be water, aqueous salt solutions, acidic or basic aqueous solutions (pH 1-10) and aqueous alcohol solutions.
- the W/O emulsion can be prepared by any art-know technique and may include an emulsifying agent suitable for stabilizing the W/O emulsion.
- the W/O emulsion contains a lipid-soluble surfactant having an HLB value less than about 5.5.
- the amount of surfactant added to generate the water-in-oil emulsion depends on the oil phase and aqueous phase that are to be dispersed.
- solvent used in the methods described herein means any liquid having the capacity to solubilize the matrix compound.
- the solvent must, however, be volatile in that the solvent must be removable from the matrix compound/oleaginous material combination by application of a vacuum without application of high temperatures. It is preferred that process temperatures be maintained below about 50°C.
- Solvents can include but are not limited to water, aqueous alcohols, alcohols, acidic and basic aqueous solutions and organic solvents, like chloroform. Water and aqueous solutions are preferred solvents for all matrix compounds.
- chloroform is a preferred solvent for PVPs. Water is the preferred solvent for processing of self-emulsifying glasses which contain water-in-oil emulsions.
- the solvent is chosen to be suitable for the desired application, keeping in mind that residual levels of solvent can be retained in the self-emulsifying glass and product emulsions, and to be compatible with the other components of the formulation.
- the "aqueous phase” is added to the self-emulsifying glass to generate an emulsion.
- the aqueous phase can solubilize the matrix compound.
- the aqueous phase must contain water and is preferably at least about 5% by weight water.
- the aqueous phase can include but is not limited to neutral, acidic and basic aqueous solutions preferably ranging in pH from 1-10, and organic compounds that are soluble in or miscible with water.
- the aqueous phase can contain such organic compounds, alone or as a mixture with each other, in combination with water.
- the aqueous phase is selected based on the desired application and to be compatible with the other components of the formulation.
- Active ingredients refers to the compound of interest which is optionally carried, or solubilized, in one of the phases of the emulsions.
- An active ingredient can be water-soluble or lipid-soluble.
- Lipid-soluble active ingredients can be solubilized in the oleaginous material including the oil phase of the primary emulsions employed as oleaginous materials.
- Water-soluble active ingredients can be solubilized in any external or internal aqueous phase of the emulsions of the present invention. Active ingredients include among others chemical reactants, catalysts, including enzymes and biological cells, inks, dyes, chelating agents, complexing agents, pharmaceutical agents, food additives, flavoring agents, colorants, cosmetic agents.
- Pharmaceutical agents include among others human and animal pharmaceuticals, therapeutic enzymes, peptides, proteins, therapeutic and diagnostic antibodies, vaccines, recombinant peptides or proteins, analgesics, chemotherapeutic agents, and enzyme inhibitors.
- the amount of active ingredient in the emulsion or self-emulsifying glass is selected to be appropriate for the desired application.
- the amount introduced into the formulation is limited by the solubility of the ingredient in the aqueous or oil phase.
- the other components of the formulation will be chosen to be compatible with the active ingredient.
- any process steps employed in the preparations of glasses and emulsions containing active ingredients must be compatible with substantially retaining the activity of the active ingredient.
- Emulsions and multiple emulsions are employed to carry, transport, protect or separate active ingredients.
- Emulsions can be employed to protect moisture- or air- sensitive compounds and to protect active ingredients from chemical or biological inactivation.
- Emulsions can also mask harsh or unpleasant tastes in pharmaceutical or food emulsions or can protect a patient from irritant or toxic effect of an active ingredient.
- Emulsion can be used to isolate a desired component from a mixture or remove an undesirable or waste product from a mixture.
- the self-emulsifying glasses of the present invention comprise a matrix formed by a water- soluble, non-surface active compound, the matrix compound, throughout which an oleaginous material is dispersed.
- the solvent method for producing an self-emulsifying glass described herein is, thus, believed to allow the formation of a dispersion of a liquid oil in a matrix of a solid.
- This invention provides a method for producing self- emulsifying glasses, emulsions and multiple emulsions. As noted above, stable emulsions and stable multiple emulsions are generated by adding an aqueous phase to a self- emulsifying glass.
- the emulsion can be formed on contact with the aqueous phase and no vigorous mixing or emulsive mixing is required.
- emulsive mixing relates to vigorous mixing, vortexing, homogenizing, blending, milling and the like which is typically required to produced conventional emulsifier-containing emulsions.
- Emulsions and multiple emulsions of the present invention can be formed when desired by adding the aqueous phase to the glass which can be stored without detrimental effect for long periods of time (months) under appropriate storage conditions.
- stable emulsion refers to a liquid-liquid dispersion that is at least more stable over time to cracking or coalescence than a dispersion of the two liquid phases that is prepared (without any emulsifying agents) by vortexing, homogenizing or other emulsive mixing.
- Dependent on the liquid phases involved a non-stable dispersion will typically coalesce in minutes or over several hours; Stable emulsions, again dependent on components, will be stable to coalescence for hours or days.
- Stable emulsions again dependent on components, will be stable to coalescence for hours or days.
- stable oil-in -water emulsions of the present invention have been observed to be stable to coalescence, phase separation and cracking (if properly stored) over several months.
- the stable water-in- oil-in-water emulsions of the present invention have been observed to be stable for at least about 90 days. Stability of oil-in-water or water-in-oil can be monitored experimentally by following changes in turbidity of the emulsion. Such measurements follow particle size in the emulsion. Decreases in turbidity accompanied by visual phase separation indicate cracking of the emulsion. Assessment of the stability of a multiple emulsion is experimentally more complex. Most generally, stability can be assessed as the loss of the internal phase to the external phase, e.g., loss of the internal water phase to the external water phase in a W/O/W emulsion. Stability has been correlated with oil droplet size (Davis et al.
- Photomicrography can be employed to measure the number and size of multiple internal drops over a period of time to assess stability. Stability can also be assessed by release of certain marker compounds which indicate disruption of the internal droplets (Magdassi et al., 1984; Florence and Whitehill, 1982; Davis and Walker, 1983). Kita et al. (1977) J. Colloid Interface Sci. 62:87-94 have employed viscosity measurements to estimate the stability of multiple emulsions.
- Self-emulsifying glasses of the present invention containing PVP as the matrix compound have been found to be functional even after exposure to the high temperatures and pressures of an autoclave.
- Emulsions prepared from PVP glasses also were stable to autoclaving. This indicates that at least some of the self-emulsifying glasses of the present invention can be sterilized after preparation with detrimental effect to functionality for emulsion formation.
- Self-emulsifying glasses are produced using a solvent method which is believed to result in a glass which is a dispersion of the liquid oil in a solid matrix.
- the method involves combining a water-soluble, non-surface active matrix compound with an oleaginous material and a sufficient amount of a solvent to dissolve the matrix compound and form a combination.
- the solvent is then removed from the combination, preferably by application of a vacuum, to give a glass.
- Solvent removal is preferably done via rotoevaporation.
- the glass is formed as a solid foam, a film or as a powder on removal of the solvent. The glass can retain some residual level of solvent.
- An alternative procedure involves adding a solvent that will dissolve both the matrix compound and the oleaginous material.
- This method can be applied when PVPs are the matrix compounds and chloroform is employed as the solvent.
- the alternative method is not useful when the oleaginous material is a water-in-oil emulsion. Water or aqueous solutions are preferred for use when a water-in-oil emulsion is combined with a matrix compound.
- a matrix compound is combined with an oleaginous material. It is preferred that the weight ratio of matrix compound to the oil in the oleaginous material be at least about 2:1.
- the oleaginous material is substantially oil, in cases in which a two phase emulsion system is desired.
- the oleaginous material is a water-in-oil emulsion, for example, it will contain substantial amounts of an internal aqueous phase, and can be up to about 30%-40% by weight.
- the oil in the emulsion oleaginous phase is correspondingly decreased. It is the oil to matrix weight ratio that is important in optimizing the quality of the self-emulsifying glass.
- the weight ratio of matrix to oleaginous material can be as low as about 1.2:1.
- the matrix compound to oil weight ratio is lower than about 2:1, the glass formed by removal of solvent may be coated with residual oil. This residual oil is not necessarily incorporated into the emulsion formed when an aqueous phase is added to the glass. The residual oil may remain as a separate, non-dispersed phase which can be undesirable for certain application. It is more preferred that the weight ratio of matrix compound to oleaginous material is from about 2:1 to 20:1 and even more preferred that the ratio be between about 2:1 and 10:1.
- the resultant solid should be a glass. It is believed that this is achieved if the rate of removal of the solvent is faster than the rate of crystallization of the matrix compound out of the solution. As noted above, regions of microcrystallinity in the glass are tolerated, and even preferred, in the glass without disruption of its self-emulsifying capability. Substantial long range order through crystal formation can affect selfemulsifying capability. It is preferred that the glasses of the present invention contain no substantial long range order. In particular, it is preferred that glasses are amorphous as determined by X-ray diffraction techniques, i.e., that they are less than about 10% by weight crystalline.
- Solvent is preferably removed from the combination until a dry-appearing solid, foam or film is generated.
- a dry-appearing solid, foam or film is generated.
- trehalose is employed as a matrix compound
- a glass having a wet appearance can give a functional self-emulsifying glass.
- a material that remains a syrup after extensive solvent removal will not give an emulsion on addition of an aqueous phase.
- Such syrups were the result of processing of mannitol and glucose by this solvent method employing water as a solvent.
- the self-emulsifying glass that results from solvent removal from a combination of a matrix compound and a water-in-oil emulsion has a dry appearance. However, the glass retains an internal aqueous phase which is not removed during solvent removal.
- a stable emulsion is not formed during the processing steps of the present invention which result in the selfemulsifying glass.
- the glass is not a dried emulsion or pre-emulsion as those terms are employed conventionally in the art.
- the combination formed with the matrix compound and the oleaginous material is not a stable emulsion.
- the processing steps of the solvent method of the present invention can be preformed at about room temperature. Processing is preferably done at temperatures less than about 50°C. Processing using the solvent method avoids the use of high temperatures that can decompose matrix compounds, oils or decompose or inactivate active ingredients.
- the solvent method avoids temperatures at which the matrix compound melts or decomposes. The method should be performed below the melting point of the matrix compound. Most matrix compounds of the present invention will melt above about 140oC.
- the methods and compositions of the present invention are particularly useful when a temperature sensitive active ingredient is employed.
- temperature sensitive relates to any detrimental effect of temperature on an active ingredient including partial or full inactivation, partial or full decomposition or partial or full denaturation.
- Some active ingredients, particularly some biological materials, will be sensitive even at room temperature. The present method is useful with such active ingredients, since it limits their exposure to higher temperatures.
- solid-liquid dispersions can also be produced by combining the liquid oil with a melt of the solid matrix compound, i.e., via a melt fusion process.
- the combination of a solid melt with a liquid oil is likely to result in a fully amorphous material, lacking any measurable microcrystallinity.
- Any saccharide, disaccharide, sweetener or sugar alcohol matrix compound of the present invention should produce a self-emulsifying glass when combined with an oleaginous material via a melt fusion process.
- a melt fusion process should also be applicable to the formation of self-emulsifying glasses from lactose, glucose, maltose, mannitol and sorbitol which were not successfully processed by the water-based solvent method of the present invention.
- the melt process has significant disadvantage over the solvent method since rather high temperatures (over about 100oC) must be employed to melt the matrix compound.
- a melt process is also not preferred for use in the preparation of glasses which contain any temperature sensitive components. Compounds, including PVP, cellulose derivatives or maltodextrins, which decompose on melting (or at temperatures close to the melting point) would not be preferably employed as a matrix in a melt fusion process.
- the melt process would not be preferred in the production of glasses which incorporate temperature-sensitive active ingredients.
- melt process can, however, be useful in expanding the range of matrix compounds, at least to the sugars and sugar alcohols, from which a self-emulsifying glass can be prepared.
- a melt fusion process is, however, not expected to be applicable to the preparation of selfemulsifying glasses that contain water-in-oil emulsions as these primary emulsions are not likely to be stable to the high temperatures required.
- Glasses of the present invention can be used in a wide variety of applications, including drug delivery, cosmetics, foods and food additives, personal care products, toxic and hazardous waste treatment, and continuous extraction systems.
- the present glass can be used to increase solubility of slightly water soluble compounds, to increase absorption of pharmaceuticals, to mask unpleasant tastes, to protect moisture sensitive compounds, to protect water soluble compounds from acidic and basic environments, to prevent gastrointestinal irritation and to reduce toxicity of a variety of compounds.
- Glasses of the present invention can be used as delivery agents for many active ingredients which are either lipidsoluble or soluble in aqueous systems, including transferase inhibitors, cephalosporins, chemotherapeutic agents, anticoagulants, thrombolytic agents, colony stimulating factors, dismutases, erythropoietins, human growth hormones, enzymes, vaccines, interferons, interleukins, monoclonal antibodies, peptides, insulin, LH- RH analogs, tumor necrosis factors, factor VIII, epidermal growth factor, insulin-like growth factor, rCD 4 , and other drugs.
- active ingredients which are either lipidsoluble or soluble in aqueous systems, including transferase inhibitors, cephalosporins, chemotherapeutic agents, anticoagulants, thrombolytic agents, colony stimulating factors, dismutases, erythropoietins, human growth hormones, enzymes, vaccines, interferons, interleukins, mono
- Embodiments of the present invention are useful as drug delivery agents that also protect active ingredients from degradation, help limit toxicity, and even to mask unpleasant tastes.
- Glasses of the present invention can also be used to deliver peptides and proteins orally, including insulin and LH-RH Analogs, such as leuprolide, analogs of gonadotropinreleasing hormone, which are useful in treating advanced prostatic cancer.
- the present invention can be used to create stable, solid-phase doses of peptides, including insulin, that can be administered orally, thus obviating the need for injections for hundreds of thousands of patients.
- the present invention makes stable, solidphase oral doses available for ceftriaxone, a third generation cephalosporin which is the drug of choice for gonorrhea, and also used extensively for infections caused by Enterobacter, Serratia, Haemophilus influenza and other bacteria.
- Ceftriaxone is readily soluble in water (ca 40g/10ml at 25°C) but it is not orally active due to its instability to acid.
- the present invention can also be used to provide a stable, solid-phase vehicle for delivery of lipoxygenase inhibitors, water insoluble compounds that inhibit arachidonic acid from being converted into various leukotrienes. Leukotrienes are possible mediators for asthma, allergic reactions, pain, and others.
- a glass of the present invention allows for delivery of lipoxygenase inhibitors readily into a patient's system.
- a glass of the present invention can also be used to deliver ACAT inhibitors (acyl transferase inhibitors) such as Belfosdil.
- ACAT inhibitors are a new class of compounds that inhibit cholesterol absorption from the gastrointestinal tract. They are usually oil soluble, but a glass of the present invention allows oral delivery in solid form.
- acetaminophen is an antipyretic and analgesic with a documented bitter taste. Its solubility is 1g/70ml water, but its bitter taste is an obstacle to oral administration. A glass made according to the present invention, incorporating acetaminophen masks this bitterness. Glasses of the present invention are also useful to increase absorption of various pharmaceuticals, including, for example, beta-blockers such as labetalol and trandate. Labetalol is a nonselective alpha and beta blocker that is used for hypertension and angina pectoris. It is water soluble (about 20 mg/ml) and is usually administered orally, however, its oral bioavailability is only about 25%, due to its extensive first pass metabolism.
- glasses of the present invention are useful for increasing absorption of chemotherapeutic agents, such as 5FU (5-Fluorouracil).
- 5FU is a chemotherapeutic agent that acts as an antimetabolite. It is the antineoplast of choice in the treatment of colorectal cancer and in combination with other drugs, it provides chemotherapy of first choice in the treatment of breast cancer, squamous cell carcinoma of the head and neck, non-small cell carcinoma of the lung, testicular and prostatic carcinomas, and others. It is administered intravenously and topically. Oral administration is desirable but presently not possible due to high first pass elimination. Its water solubility is 1g/80ml water, with the solubility in aqueous solutions increasing with increasing pH.
- Glasses of the present invention are useful for administering drugs having toxicity, such as Methotrexate and Mechlorethamine HCl.
- Methotrexate (MTX) is a chemotherapeutic agent that acts as an antimetabolite. It is the antineoplastic of choice for CNS prophylaxis in acute lymphocytic leukemia. It is a component of the first-choice combination for induction and maintenance in acute lymphocytic leukemia, cervical cancer, breast cancer, non-Hodgkin's lymphomas and Burkitt's lymphoma.
- Mechlorethamine HCl is an alkylating agent called a nitrogen mustard.
- MOPP mechlorethamine, vincristine, procarbazine, prednisone
- MOP MOPP without prednisone
- Glasses of the present invention when used as drug delivery agents can be administered to humans or animals in a variety of forms, including dry powder form, encapsulated, compressed into tablet form, solid foam form, and emulsion form.
- Fluorodecalins have been used in connection with blood substitutes, including perfluorodecalins, however, they are problematic in that they form unstable emulsions requiring high levels of surfactants. Emulsions of the present invention using perfluorodecalin are more stable and are formed without the use of a surfactant. The multiple emulsions made according to the present invention are effective at solubilizing hemoglobin, thus providing new blood substitutes.
- Emulsions of the present invention are useful as continuous extraction agents.
- the emulsions of the present invention help to separate enzymes or cells from waste products or cell products continuously.
- Emulsions of the present invention are useful in continuous extraction systems to separate heavy metals, e.g., by the creation of a gradient to pull heavy metals into the interior phase of the emulsion.
- Such systems may utilize, for example, proton shift or chelate technology in the interior phase.
- a related use of the glasses of the present invention is in the area of enzyme immobilization.
- Sucrose (2.2 g) was mixed with a volume of doubly distilled water sufficient to dissolve it. Heavy mineral oil (USP, 0.5 g) was then added to this solution. The mixture was rotoevaporated with application of mild heating (i.e., at temperatures less about 50°C). The resulting solid had a fluffy appearance. When about 2 ml of doubly distilled water was added to about 200 mg of the solid, an oil-in-water emulsion was readily formed. The oil-in-water emulsion incorporating sucrose was found to have little or no detectable sweet-taste in a qualitative taste test.
- Sucrose (2.0 g) was mixed with 0.5 g of olive oil and a volume of doubly distilled water sufficient to dissolve the sucrose. The resulting mixture was rotoevaporated until dry giving a clear film which lined the flask. A sufficient amount of doubly distilled water was added to the film-lined flask to result in oil-in-water emulsion.
- an aqueous phase required to be added to a particular self-emulsifying glass in order to form an oil-in-water emulsion can be readily determined by qualitative visual inspection or by more quantitative measurement.
- an oil-in-water emulsion in which the external phase is water or an aqueous solution, will have certain bulk properties like that of an external aqueous phase, for example, the emulsion will not visually appear oily or feel oily to the touch.
- a more quantitative assay of whether or not water is the external phase involves addition of a small amount of a water-soluble dye to the emulsion. If the colored dye disperses in the external phase (i.e., the emulsion becomes colored) it is an aqueous phase.
- the actual amount above the minimum of an aqueous phase that is added to form an oil-in-water emulsion depends on the desired application of the emulsion.
- Progesterone (0.5 g) was dissolved in 0.5 g safflower oil. Sucrose (2.0 g) was combined with the progesteroneoil solution. Doubly distilled water was then added in an amount sufficient to dissolve the sucrose. The resulting combination was rotoevaporated in a flask containing a stir bar until dry. The resulting solid, when combined with water, formed a oil-in-water emulsion having progesterone in the oil phase. A similar preparation was made using mineral oil in place of safflower oil. The progesterone was observed to be more soluble in safflower oil than in mineral oil.
- Linear PVP molecular weight about 30,000
- heavy mineral oil USP
- An amount of chloroform sufficient to dissolve both the oil and the PVP was added.
- the resulting solution was left to stand at room temperature to allow the solvent to evaporate giving a dry solid.
- Doubly distilled water was added to the dry solid and a oil-in-water emulsion was formed.
- a similar dry solid material can be prepared by removal of the solvent by rotoevaporation.
- the cyclamate and saccharin-based emulsions were found to retain a sweet taste by qualitative direct tasting of the emulsions.
- the emulsions were significantly less sweet- tasting, however, than equivalent amounts of the sweeteners themselves.
- Example 8 Preparation of Stable Oil-in-Water Emulsions with 95% Aqueous Ethanol. 1 N HCl and 1 N NaOH
- a self-emulsifying glass was prepared by rotoevaporating a mixture of sucrose, heavy mineral oil (USP) and doubly distilled water; the weight ratio of sucrose to mineral oil in the mixture and the result and glass was 4:1.
- Emulsion Stability Sucrose and castor oil were combined in a 2:1 weight ratio. An amount of doubly distilled water sufficient to dissolve the sucrose was added. The resulting mixture was rotoevaporated to produce a dry non-oily solid. About 200 mg of the dry solid glass was added to about 2 ml of doubly distilled water to form an oil-in-water emulsion. Thereafter, the emulsion was successively frozen at about -7°C and thawed at about 25°C at least 40 times. The emulsion was not cracked by this treatment. After each freeze-thaw cycle, the light scattering, a function of the particle size of the emulsion, was indirectly determined using a Baush and Lomb Spectrophotometer 100. The repeated freeze-thaw cycles did not affect the particle size of the emulsion.
- Example 10 Stability of a Sucrose-Mineral Oil Emulsion
- a self-emulsifying glass was prepared as described above in Example 2, with sucrose and mineral oil in the ratio of 6:1. Distilled water or normal saline were added to the glass to produce oil-in-water emulsions.
- a physical mixture of oil, sucrose and water in the same weight ratios as in the emulsions prepared from the glasses was subjected to emulsive mixing, i.e., vigorous vortexing, for 20 minutes to produce a dispersion.
- the turbidity (at 400 nm) of the two emulsions and the dispersion were compared as a function of time (up to about 22 hrs).
- Each transmission measurement was corrected for drift with a reference tube containing 3 ml of doubly distilled water.
- the turbidity of the sample provides a measure of the particle size of an emulsion. Furthermore, the turbidity of a sample will decrease on cracking of an emulsion or disruption of a dispersion. A change in particle size is distinguished from emulsion cracking as emulsion cracking is accompanied by visual phase separation.
- Example 11 Stability of a PVP:Mineral Oil Emulsion
- Heavy mineral oil (USP) and linear PVP (molecular weight about 30,000) were mixed in a weight ratio of 1:5. An amount of analytical grade methanol sufficient to dissolve the PVP was added to the combined oil and PVP. The resulting mixture was rotoevaporated to remove methanol. The resulting solid (100 mg) was combined with about 3 ml doubly distilled water to form an oil-in-water emulsion. For comparison to the above described emulsion, dispersions of heavy mineral oil (USP) and linear PVP
- the turbidity (% Transmission at 400 nm) of the emulsion and the two dispersions produced as described were measured as a function of time up to about 22 hours as described in Example 10, and the systems were visually observed for any physical changes, e.g., phase separation.
- the emulsion formed from the PVP:oil self-emulsifying glass was considerably more stable than either of the dispersions prepared. In both the vortexed and the colloid mill-prepared dispersion a rapid phase separation was observed within at most 5 min. The emulsion was, in contrast, found to be stable to phase separation for at least about 20 hours.
- the relative conductivity of the emulsions of the present invention above the "fluctuating" region is greater than 1, i.e., the continuous phase has a conductivity greater than that of bulk water. It is believed that this is due to an imposition of an order or structure on the water external phase by the emulsion particles at higher water content, possibly via the formation of liquid crystals, whereby the water phase more readily conducts current.
- the lower conductivities below the fluctuating region is associated with a more complex structure and less entropy.
- Example 13 Effect of Shear Stress on Emulsion Structure as Measured by Viscosity
- Example 14 Viscosity of Sucrose-Mineral Oil Emulsion as a
- the viscosities of a sucrose-mineral oil emulsion prepared as in Example 2, as a function of temperature were compared to those of control sucrose solutions.
- the emulsion was prepared by adding 1 ml of doubly distilled water to 0.5224 g of the glass produced in Example 2.
- a sucrose solution was prepared by dissolving an amount of sucrose equivalent to that amount present in 0.5524 g of the glass (0.450 g) in 1 ml water. Viscosity measurements were then made for both samples as the temperature was lowered from 40°C to 5°C. All viscosity measurements were made with a Brookfield cone/plate viscometer with a spindle speed of 60 rpm. The results are presented in Table II:
- Example 15 Viscosity of a Water-in-Oil Emulsion as a
- Heavy mineral oil (USP, 0.25 g) was mixed with 1.25 g of linear PVP (molecular weight about 30,000) and about 200 ml of analytical grade methanol. This mixture was then rotoevaporated until dry. An emulsion was generated by the addition of water to several milligrams of the resulting solid. The particle size of the emulsion was determined by a Hiac/Royco particle size analyzer to be between about 0.5 and about 5.0 ⁇ m, with the size averaging about 4 ⁇ m.
- Example 17 Rate of Formation of a PVP-Mineral Oil Emulsion
- doubly distilled water (3 ml) was added at time zero to a sample of the solid (127.5 mg) without mixing and the turbidity of the sample was measured. The absorbance of the samples was measured periodically. Table III summarizes the results.
- the data also indicate that a wavelength of 400 nm does produce a Tyndall effect with these emulsion particles. Thus, at least some of the particle sizes in the emulsion must be greater than 400 nm (0.4 ⁇ m). The emulsions had a cloudy appearance, indicating the presence of particles having a diameter greater than 0.05 ⁇ m (the lower limit of visibility with the naked eye).
- the sample was stored at room temperature for 2 weeks. After this time, it was observed that the samples had become transparent even though the emulsion had not undergone phase separation. This further suggested that particle size of the emulsions had decreased over time, to form a emulsion with a particle size less than about 0.05 ⁇ m.
- the X-ray diffractograms of a sucrose-mineral oil solid produced by the method of the subject invention and of a simple mixture of sucrose and mineral oil were obtained.
- Each sample contained sucrose and heavy mineral oil (USP) in a weight ratio of 3.5:1.
- the oil and sugar were manually mixed.
- sample 2 a quantity of doubly distilled water sufficient to dissolve the sucrose was added, and the water was then removed by rotoevaporation, as described hereinabove, to produce the self-emulsifying solid.
- Each sample was then packed into a 1 X 3 cm sample holder and run on a Scintag/USA Powder X-ray Diffractometer, Cuk ⁇ , wavelength 1.54 ⁇ , and scan rate of 3 oC/minute.
- the diffractograms for each sample are presented in Figure 4.
- the diffractograms indicate that the sucrose in the simple mixture retains its crystalline structure, as expected.
- the processed sucrose and mineral oil glass appears amorphous by this experimental technique.
- the X-ray diffraction technique can detect more than about 10% long range molecular order from crystal formation.
- Diffractograms of sucrose-mineral oil solid emulsions having sugar to oil weight ratios of 2.5:1 and 4:1 were also measured. These self-emulsifying solids also appear to be amorphous by X-ray diffraction.
- sucrose-mineral oil solid emulsion of Example 2 was added about 2 ml of doubly distilled water to form the emulsion.
- An additional 2 ml of heavy mineral oil (USP) was subsequently added to the emulsion.
- the additional oil was observed to readily disperse in the system; there was no evidence of phase separation.
- the dispersion took place without the addition of work (e.g., stirring) to the system.
- work e.g., stirring
- a primary emulsion was prepared by emulsifying an aqueous solution with heavy mineral oil to which a lipid soluble surfactant: Arlacel-C, Span 80 or Span 85
- Emulsions having 70%-79% wt/wt heavy mineral oil, 5.5%-7.2% wt/wt surfactant (HLB 1.8-4.3) and 21%-30% of an aqueous phase were prepared.
- Sucrose was combined with the primary W/O emulsion in the weight ratio about 78:22. Doubly distilled water was then added to dissolve the sucrose. The combination was subjected to rotoevaporation (at about 5 mmHg). The flask containing the combination was rotated at about 17-25 rpm on the rotoevaporator and the temperature of the flask was maintained at about 32°C. Water was removed from the combination until a dry "foam-like" material was produced.
- the solid was collected as a powder and stored in a desiccator at room temperature. It has been found that the solid self-emulsifying glass can be stored in this way for relatively long times (weeks or months) without loss of its self-emulsifying property.
- Addition of an aqueous phase to the solid results in formation of multiple W/O/W emulsion.
- addition of 5 ml of water, 1 N HCl, or 1 N NaOH to 1 g of solid results in the formation of a stable multiple emulsion.
- the solid is not dispersed in heavy mineral oil; the solid settles to the bottom of the container of mineral oil, since the density of the glass solid is greater than that of oil. This result is consistent with the solid containing internal droplets of water or aqueous phase (of the primary emulsion).
- thermogram A The glass transition of the glass was found to be approximately 57°C with recrystallization of sucrose observed at approximately 120°C and finally at approximately 185°C any crystalline sucrose in the glass melts.
- DSC analysis was performed on the self-emulsifying glasses produced using sucrose and mineral oil.
- the DSC thermograms of the sucrose-mineral oil glasses are analogous to that of the sucrose/primary emulsion glass thermogram of Figure 5, thermogram A, in that a glass transition, sucrose recrystallization and sucrose melting feature are observed.
- the relative size of the peak associated with the melting of crystalline sucrose will vary dependent on the amount of microcrystallinity in the glass.
- DSC measurement can in fact be readily employed to determine the amount of microcrystallinity in a particular glass sample.
- the glass transition temperature may vary dependent on the exact composition of the glass.
- thermogram of a physical mixture of sucrose and mineral oil exhibits no glass transition.
- the thermogram contains only a feature associated with the melting of crystalline sucrose at about 185°C.
- Example 21 Preparation of a Self-Emulsifying Glass containing Sucrose-Maltodextrin and a W/O Emulsion
- a primary emulsion was prepared as described in example 21.
- a mixture of sucrose containing 3% (wt/wt) maltodextrin was added to the emulsion in the weight ratio of about 78:22 and sufficient water was added to dissolve the sucrose/maltodextrin. Removal of the water by rotoevaporation resulted in a dry solid which was found to form a W/O/W emulsion on contact with an aqueous phase.
- addition of 5 ml of water, 1 N HCl, or 1 N NaOH results in the formation of a stable multiple emulsion.
- the glass was analyzed using differential scanning calorimetry, see Figure 5B.
- the glass transition temperature of this glass is raised significantly compared to the sucrose containing glass of the example 21 (to greater than about 180oC). No sucrose recrystallization is detected and any crystalline sucrose in the glass is observed to melt. Addition of maltodextrin to the sucrose carrier results in much higher glass transition temperatures than with sucrose alone. Higher glass transition temperatures are likely to be associated with increased stability of the self-emulsifying systems in the solid state and to result in longer shelf-life of these glasses and products based on these glasses.
- Water soluble and/or lipid soluble dyes were incorporated into self-emulsifying glasses in order to examine the structure of the emulsions that were formed from these glasses.
- Example 20 Primary emulsions were prepared as described in Example 20 with heavy mineral oil and surfactant.
- the lipid soluble dye D&C violet 2 was added to the oil phase and the water soluble dye FD&C red 17 was added to the internal aqueous phase.
- a sucrose/primary emulsion glass containing both dyes was prepared and water was added to that glass to form a W/O/W emulsion.
- the emulsion was then examined under a microscope (400 power magnification) and was found to contain a visually red internal phase and a blue-grey oil phase.
- Type A droplets having a small outer droplet surrounding one large inner droplet
- Type B droplets composed of larger exterior phases containing smaller, multiple interior droplets
- Type C droplets having an even larger exterior oil phase containing small aqueous droplets too numerous to count
- Type A, B and C droplets have been described previously in multiple emulsions (see Florence and Whitehill (1981)).
- the sucrose-based multiple emulsions examined were composed of approximately 80% Type A droplets. The remainder being either type B or C droplets.
- the particle size of these sucrose-based W/O/W emulsions was determined as a function of time after emulsion preparation. Particle size measurement were taken at preparation, at 7 days after preparation and at 30 days after preparation. The average diameters for the outer and inner membrane of the emulsion droplets were 12.4 micron and 3.9 micron, respectively immediately after emulsion preparation. These diameters did not significantly change at 7 and 30 days after preparation. The emulsions were also visually inspected under the microscope at 60 and 90 days after preparation and were found to remain intact.
- Example 23 Production of Matrix Compound - W/O Emulsion- Containing Self-Emulsifying Glasses.
- any water-soluble non-surface active matrix compound (polymer or non-polymer) of the present invention and with any water-in-oil emulsion including, among others, sucrose, fructose, trehalose, cyclamate, saccharine and the water- soluble polymers PVP cellulose derivatives and maltodextrin.
- a primary water-in-oil emulsion is formed by conventional art-known techniques employing a lipid soluble surfactant.
- Surfactants appropriate for the formation of water-in-oil emulsions are employed, specifically those having HLB values less than about 5.
- Anionic, cationic or non-ionic surfactants can be employed.
- An aqueous phase is combined with an oleaginous material and the surfactant and the primary W/O emulsion is formed by vigorous mixing (i.e., emulsive mixing).
- the primary emulsion is produced, it is combined with the desired matrix compound and an amount of an aqueous solution sufficient to dissolve the matrix compound. Water is then removed from the resulting combination to give a solid, foam or film which appears to be dry. The dry-appearing solid is found to be a selfemulsifying glass. Addition of a sufficient amount of an aqueous phase to the glass results in the formation of a stable multiple emulsion, i.e., a W/O/W emulsion.
- Table IV provides a representative list of preparations of selfemulsifying glasses containing a water-in-oil emulsion.
- phase ratios (v/v) of oil: aqueous phase in the primary emulsions employed ranged from about 4:1 to 2:1.
- non-ionic surfactants having the indicated HLB value were used, for example, Arlacel C (Trademark).
- Specifically exemplified matrix compounds are sucrose, PVP and mixtures of sucrose and maltodextrin.
- the weight ratio of matrix to emulsion specifically exemplified ranged from about 1:1 to 9:1. (Representing matrix to oil weight ratios ranging from about 1.2:1 to about 10:1.)
- the aqueous phases of the primary emulsion can range in pH from 10 to 1 and may include inorganic salts.
- the oil phase of the primary emulsion can also contain an active ingredient, usually lipid soluble.
- Example 24 W/O/W Emulsions Containing Canrenoic Acid
- emulsions were prepared by emulsifying an aqueous solution with heavy mineral oil to which the surfactant Arlacel-C (HLB 3.7, Trademark ICI Americas Inc., USA) had been added.
- the aqueous phase was prepared to be either 0.0614 M or 0.439 M in canrenoic acid K + salt.
- the surfactant was added to the oil and the mixture was homogenized using a Brinkman Homogenizer (Sybron Corporation, USA) with a small impeller attachment for 40- 60 seconds. The aqueous phase was then slowly added to the oil phase. After addition was complete, homogenization was continued until the desired water-in-oil emulsion was obtained.
- the primary emulsions contained about 71.4% mineral oil, about 21.4% aqueous phase and about 7.1% surfactant.
- Sucrose was combined with the primary W/O emulsion in the weight ratio about 78:22.
- Doubly distilled water was then added to dissolve the sucrose.
- the combination was subjected to rotoevaporation to produce a dry "foam-like" solid. Addition of water to the solid resulted in a W/O/W emulsion.
- Examination of the external water phase of the multiple emulsion employing infrared spectroscopy immediately after preparation of the emulsion detected no canrenoic acid in the external phase.
- Canrenoic acid was slowly released from the internal phase of the multiple emulsion as a function of time. Multiple emulsions such as that exemplified can function as slow release drug delivery systems.
- a lipoxygenase inhibitor is dissolved in olive oil in a flask to make a concentrated solution.
- PVP is added in the ratio of 8:4:1: : PVP:Oil solution.
- Water is added until the PVP dissolves, leaving a two-phase system.
- the water is then removed using a rotoevaporator, leaving a solid, foamy material.
- a stable O/W emulsion results.
- a lipoxygenase inhibitor is dissolved in olive oil in a flask to make a concentrated solution.
- PVP is added in the ratio of 8.4:1: :PVP:Oil solution.
- Chloroform is added until the PVP dissolves.
- the chloroform is then removed using a rotoevaporator, leaving a solid, foamy material.
- water or another aqueous phase is added to the solid, a stable O/W emulsion results.
- Example 27 Preparation of O/W Emulsion III An ACAT inhibitor is dissolved in corn oil in a flask to make a concentrated solution. PVP is added in the ratio of 3.5:1::PVP:Oil solution. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is again added to the solid, a stable O/W emulsion results.
- Example 28 Application of a O/W Emulsion to Blood Substitutes
- Perfluorodecalin an oil capable of solubilizing oxygen, is thoroughly gassed with carbon dioxide on ice. It is then mixed with PVP (22% perfluorodecalin, 78% PVP) in a flask. Cold water is added until the PVP dissolves, leaving a two-phase system. The water is then removed in a rotoevaporator, leaving a foamy solid. An aqueous solution consisting of a physiological salt solution containing NaCl (0.6%), MgCl2 (0.02%), KCl (0.03%), sodium lactate (0.31%), glucose (0.1%) is added, forming a stable O/W emulsion. The resulting oil-in-water emulsion can be employed in a blood substitute composition.
- Example 29 Preparation of W/O/W Emulsion I
- a primary emulsion of 70% vegetable oil, 7% Arlacel C and 23% aqueous solution containing insulin, glycerin and mcresol (2.5 mg/ml) is prepared in an agitator. It is mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is added to the solid foamy material, a stable W/O/W emulsion results.
- Example 30 Preparation of W/O/W Emulsion II
- a primary emulsion of 70% soybean oil, 7% Arlacel C and 23% aqueous solution containing 40% ceftriaxone at pH 6.7 is prepared in a homogenizer. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is added to the solid, a stable W/O/W emulsion results.
- a primary emulsion of 70% peanut oil, 7% Arlacel C and 23% aqueous solution containing 20 mg/ml labetalol in water at pH 2-4 is prepared in a homogenizer. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water is added again, a stable W/O/W emulsion results.
- a primary emulsion of 70% mineral oil, 7% Arlacel C and 23% aqueous solution containing 1.25% 5-fluorouracil (5FU) at pH 8.0 is prepared in a homogenizer. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is added again to the solid, a stable W/O/W emulsion results.
- Example 34 Preparation of W/O/W Emulsion VI
- a primary emulsion of 70% safflower oil, 7% Arlacel C and 23% aqueous solution containing 1 mg/ml Methotrexate (2% bovine serum albumin) is prepared in a homogenizer. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is added again to the solid, a stable W/O/W emulsion results.
- a primary emulsion of 70% light mineral oil, 7% Arlacel C and 23% aqueous solution containing 2 mg/ml mechlorethamine HCl, at pH 6 is prepared in an agitator. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water or another aqueous phase is added again to the solid, a stable W/O/W emulsion results.
- Example 36 Preparation of W/O/W Emulsion VIII; W/O/W
- a primary emulsion of 70% vegetable oil, 7% Arlacel C and 23% aqueous solution (isotonic 10MM phosphate at pH 7.1, 1% Hemoglobin) is prepared in an agitator. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Cold water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material.
- aqueous solution containing NaCl (0.6%), MgCl2 (0.02%), KCl (0.03%), sodium lactate (0.31%), and glucose (0.2%) is added, forming a stable W/O/W emulsion.
- the exemplified water-in-oil-in-water emulsion ca be employed in a blood substitute.
- Example 37 Preparation of W/O/W Emulsion IX A primary emulsion of 70% light mineral oil, 7% Arlacel C and 23% of 0.06% urease solution in water is prepared in an agitator. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water is added again, a stable W/O/W emulsion results.
- a primary emulsion of 70% light mineral oil, 7% Arlacel C and 23% aqueous solution consisting of 5 mg/ml LH-RH analog in NaCl for tonicity and 9 mg/ml of benzoyl alcohol is prepared in a homogenizer. It is then mixed in a flask with sucrose in the ratio of 3.5:1::sucrose:primary emulsion. Water is added until the sucrose dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water is added again, a stable W/O/W emulsion results.
- a primary emulsion of 70% light mineral oil, 7% Arlacel C and 23% of 2N sulfuric acid is prepared in an agitator. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water is added again, a stable W/O/W emulsion results which is useful in continuous flow extraction for cationic toxic materials.
- a primary emulsion of 70% light mineral oil, 7% Arlacel C and 23% of aqueous phase with 10% EDTA is prepared in an agitator. It is then mixed in a flask with PVP in the ratio of 3.5:1::PVP:primary emulsion. Water is added until the PVP dissolves, leaving a two-phase system. The water is then removed using a rotoevaporator, leaving a solid, foamy material. When water is added again, a stable W/O/W emulsion results which is useful in continuous flow extraction for toxic materials that can form complexes with chelate.
- Example 41 Drug Delivery using Self-Emulsifying Glasses
- a self-emulsifying glass is prepared by the method of Example 2 from a mixture of sucrose and an oil suitable for pharmaceutical applications and internal administration, such as mineral oil. All preparation are done under conditions appropriate for the preparation of human pharmaceuticals. The ratio of sucrose to oil is at least about 2:1.
- a lipid-soluble active ingredient which has medicinal activity, i.e., a lipid-soluble drug, is dissolved in the oil phase prior to processing to form the glass. Processing conditions are such that the activity of the drug is substantially unaffected.
- the resultant glass incorporates the lipid-soluble active ingredient.
- the glass is introduced into a capsule or other similar means appropriate for administration of solid drug agents to humans or animals.
- the amount of glass solid in the capsule is adjusted to provide a desired dosage.
- the capsule may also include an appropriate filling agent.
- the concentration of active ingredient in the oil phase can be adjusted to achieve a desired dosage range.
- the resultant capsule is orally administered to the human or animal patient to provide a desired dose of the medicinal agent.
- a self-emulsifying glass prepared as described above to contain a lipid-soluble drug can be employed in the preparation of tablets for oral drug administration.
- Example 42 Drug Delivery using Self-Emulsifying Glasses
- a self-emulsifying glass is prepared by the method of Example 2 from a mixture of sucrose and an water-in-oil emulsion suitable for pharmaceutical applications and internal administration. All preparations are done under conditions appropriate for the preparation of human pharmaceuticals.
- the ratio of sucrose to oil in the water- in-oil emulsion is at least about 2:1.
- a water-soluble active ingredient which has medicinal activity i.e., a water soluble drug, is dissolved in the aqueous phase prior to formation of the water-in-oil emulsion. Processing conditions are such that the activity of the drug is substantially unaffected.
- the resultant glass incorporates the water soluble active ingredient.
- the glass is introduced into a capsule or other similar means appropriate for administration of solid drug agents to humans or animals.
- the amount of glass solid in the capsule is adjusted to provide a desired dosage.
- the capsule may also include an appropriate filling agent.
- the concentration of active ingredient in the aqueous phase of the water-in-oil emulsion can be adjusted to achieve a desired dosage range.
- the resultant capsule is orally administered to the human or animal patient to provide a desired dose of the medicinal agent.
- a self-emulsifying glass prepared as described above to contain a water soluble drug can be employed in the preparation of tablets for oral drug administration.
- Sucrose is mixed with a volume of aqueous solution sufficient to dissolve it.
- the aqueous solution contains water-soluble ingredients suitable for food preparations, including a flavoring agent such as vanilla extract.
- an oil suitable for use in food preparations such as vegetable oil.
- a lipid-soluble ingredient, such as a flavoring agent, is dissolved in the oil prior to mixing with the sucrose solution.
- the ratio of sucrose to oil is at least about 2:1.
- the mixture is subjected to evaporation to remove the water, leaving a glass solid.
- the glass solid is mixed with other food ingredients, including flour, additional sugar, baking soda, spices, and baking powder. This mixture is then stored until needed for preparation into the final food product. When needed, the mixture is mixed with water to form a batter suitable for baking a cake or similar preparation. No egg or other emulsifying agent is needed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions et procédé servant à la préparation d'émulsions et d'émulsions multiples. On décrit plus particulièrement des solides qui sont des verres autoémulsifiants et qui, en contact avec une quantité suffisante d'une phase aqueuse, forment des émulsions ou des émulsions multiples sans l'adjonction d'un mélange émulsifiant. La présente invention a trait aux émulsions et aux émulsions multiples produites à partir des verres autoémulsifiants. Les verres autoémulsifiants sont préparés à partir de certains composés matriciels et d'une matière oléagineuse avec un procédé par solvant. Le verre résulte de l'élimination du solvant dans une combinaison de composé matriciel, d'une matière oléagineuse et d'un solvant qui dissout pratiquement tout le composé matriciel. Les émulsions multiples résultent de verres dont la phase oléagineuse est une émulsion primaire, c'est-à-dire une émulsion eau-dans-huile. Les verres et les émulsions ainsi produits sont particulièrement utiles pour des applications pharmaceutiques, alimentaires et cosmétiques.Compositions and method for preparing multiple emulsions and emulsions. More particularly described are solids which are self-emulsifying glasses and which, in contact with a sufficient quantity of an aqueous phase, form emulsions or multiple emulsions without the addition of an emulsifying mixture. The present invention relates to emulsions and multiple emulsions produced from self-emulsifying glasses. Self-emulsifying glasses are prepared from certain matrix compounds and an oleaginous material with a solvent process. Glass results from the removal of the solvent in a combination of matrix compound, an oilseed and a solvent which dissolves virtually all of the matrix compound. Multiple emulsions result from glasses of which the oleaginous phase is a primary emulsion, that is to say a water-in-oil emulsion. The glasses and emulsions thus produced are particularly useful for pharmaceutical, food and cosmetic applications.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53184790A | 1990-06-01 | 1990-06-01 | |
US531847 | 1990-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0489898A1 true EP0489898A1 (en) | 1992-06-17 |
EP0489898A4 EP0489898A4 (en) | 1993-06-09 |
Family
ID=24119305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19910912696 Withdrawn EP0489898A4 (en) | 1990-06-01 | 1991-05-31 | Self-emulsifying glasses |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0489898A4 (en) |
JP (1) | JPH07501259A (en) |
AU (1) | AU648573B2 (en) |
CA (1) | CA2059555A1 (en) |
IE (1) | IE62921B1 (en) |
WO (1) | WO1991018613A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516537A (en) * | 1987-04-20 | 1996-05-14 | Fuisz Technologies Ltd. | Frozen comestibles |
FR2649012B1 (en) * | 1989-07-03 | 1991-10-25 | Seppic Sa | INJECTABLE MULTIPHASIC EMULSIONS |
US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5196199A (en) * | 1990-12-14 | 1993-03-23 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and method of manufacture |
US5268110A (en) * | 1991-05-17 | 1993-12-07 | Fuisz Technologies Ltd. | Oil removing method |
CA2125579C (en) * | 1991-12-17 | 2005-06-21 | Richard C. Fuisz | Ulcer prevention treatment composition and method |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
AU3924193A (en) * | 1992-03-19 | 1993-10-21 | Allergan, Inc. | Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US5518551A (en) * | 1993-09-10 | 1996-05-21 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5597416A (en) * | 1993-10-07 | 1997-01-28 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5480914A (en) * | 1994-05-06 | 1996-01-02 | Allergan, Inc. | Nonaqueous thixotropic drug delivery suspensions and methods of their use |
FR2720943B1 (en) * | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Stable inverse emulsions with a high concentration of fluorinated compound (s) and their use for the pulmonary administration of medicaments and for the manufacture of multiple emulsions. |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
DE60003633T2 (en) * | 1999-01-12 | 2004-06-03 | Merck Sharp & Dohme Ltd., Hoddesdon | SPHERONIZED SELF-REGULATING SYSTEM FOR HYDROPHOBIC AND WATER-SENSITIVE ACTIVE SUBSTANCES |
EP1175205B1 (en) | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
DE10026698A1 (en) * | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
ITMI20011756A1 (en) * | 2001-08-09 | 2003-02-09 | Remedia S R L | PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE WATER / OIL / WATER MICROEMULSION INCORPORATED IN A SOLID SUPPORT |
AU2002349035A1 (en) * | 2001-12-12 | 2003-06-23 | Unilever N.V. | Emulsified food compositions |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP1893182B8 (en) | 2005-05-26 | 2012-04-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and method of making and using the same |
FR2902995B1 (en) * | 2006-06-29 | 2008-09-12 | Lessonia | EXTREMELY EMULSIONABLE PREPARATION BASED ON ACTIVE INGREDIENTS, FOR COSMETOLOGY, DERMATOLOGY OR SPA |
FR2947178B1 (en) * | 2009-06-29 | 2012-07-06 | Effik | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF |
EP2488022B1 (en) | 2009-10-16 | 2018-01-10 | Mochida Pharmaceutical Co., Ltd. | Compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
US3148127A (en) * | 1960-05-16 | 1964-09-08 | American Home Prod | Aqueous pvp solution in two phase aerosol hair spray |
US3136692A (en) * | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
US3145146A (en) * | 1961-10-31 | 1964-08-18 | Warner Lambert Pharmaceutical | Modified mannitol for pharmaceutical tablets |
US4199564A (en) * | 1978-09-22 | 1980-04-22 | Masti-Kure Products Company, Inc. | Film-forming alcoholic microbicidal teat dip and method of use thereof |
US5011532A (en) * | 1988-03-18 | 1991-04-30 | Fuisz Pharmaceutical Ltd. | Dispersed systems and method of manufacture |
US4963385A (en) * | 1989-06-02 | 1990-10-16 | Nabisco Brands, Inc. | Stabilized emulsions containing highly unsaturated oils |
-
1991
- 1991-05-31 AU AU82106/91A patent/AU648573B2/en not_active Ceased
- 1991-05-31 WO PCT/US1991/003864 patent/WO1991018613A1/en not_active Application Discontinuation
- 1991-05-31 EP EP19910912696 patent/EP0489898A4/en not_active Withdrawn
- 1991-05-31 JP JP3511745A patent/JPH07501259A/en active Pending
- 1991-05-31 CA CA 2059555 patent/CA2059555A1/en not_active Abandoned
- 1991-06-04 IE IE190191A patent/IE62921B1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO9118613A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2059555A1 (en) | 1991-12-02 |
IE911901A1 (en) | 1991-12-04 |
WO1991018613A1 (en) | 1991-12-12 |
IE62921B1 (en) | 1995-03-08 |
JPH07501259A (en) | 1995-02-09 |
EP0489898A4 (en) | 1993-06-09 |
AU8210691A (en) | 1991-12-31 |
AU648573B2 (en) | 1994-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU648573B2 (en) | Self-emulsifying glasses | |
KR900003557B1 (en) | Micro emulsion composition | |
CA2193497C (en) | Controlled release aqueous emulsion | |
KR880000970B1 (en) | Method for preparing oral pharmaceutical composition with high bioavailability | |
US4794000A (en) | Coacervate-based oral delivery system for medically useful compositions | |
DE69431831T2 (en) | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE ACTIVE SUBSTANCES AND METHOD FOR THEIR PRODUCTION AND USE | |
Westesen | Novel lipid-based colloidal dispersions as potential drug administration systems–expectations and reality | |
JP2000191684A (en) | Method for producing dispersible sterol and stanol compositions | |
JP2007510657A (en) | Process for preparing submicron particles of paclitaxel | |
JPH0774145B2 (en) | Emulsion composition containing crystalline drug | |
US5635491A (en) | Lyophilized fatty emulsions and a process for the production thereof | |
JPH08208522A (en) | Pharmaceutical carrier | |
RU2275908C2 (en) | New self-emulsified drug delivery system | |
JPS5924132B2 (en) | Manufacturing method for nutritional supplement emulsion | |
US8252326B2 (en) | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 | |
Im-Emsap et al. | Disperse systems | |
KR102102098B1 (en) | A composition of emulsion preconcentrate comprising protopaxadiol | |
JPH06165931A (en) | Self-emulsification-type glass | |
Deepak et al. | Recent advancement, technology & applications of the multiple emulsions | |
JP4008965B2 (en) | Preparation of lecithin-containing fat emulsion | |
Aleem | Solid Dispersion–An Approach To Enhance The Dissolution Rate Of Aceclofenac | |
Bhange | Self-emulsifying Drug Delivery System for Improvement of Solubility of Drug | |
JP3611130B2 (en) | Preparation method of fat emulsion | |
KR19980031601A (en) | Method of solubilizing poorly soluble drugs | |
Sharma et al. | Sistema de administración de fármacos autoemulsionante: una estrategia para mejorar la biodisponibilidad oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 9/107 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19930422 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19940927 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960911 |